Dropout in a longitudinal, cohort study of urologic disease in community men

被引：21
作者：
Gades N.M. [1 ]
Jacobson D.J. [2 ]
McGree M.E. [2 ]
Lieber M.M. [3 ]
Roberts R.O. [1 ]
Girman C.J. [1 ,4 ]
Jacobsen S.J. [5 ]
机构：
[1] Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN
[2] Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN
[3] Department of Urology, Mayo Clinic College of Medicine, Rochester, MN
[4] Department of Epidemiology, Merck Research Laboratories, Blue Bell, PA
[5] Research and Development, Southern California Permanente Medical Group, Pasadena, CA
来源：
BMC Medical Research Methodology | / 6卷 / 1期
关键词：
Erectile Dysfunction; Benign Prostatic Hyperplasia; Lower Urinary Tract Symptom; Urinary Symptom; Urethral Stricture;
D O I：
10.1186/1471-2288-6-58
中图分类号：
学科分类号：
摘要：
Background: Reasons for attrition in studies vary, but may be a major concern in long-term studies if those who drop out differ systematically from those who continue to participate. Factors associated with dropout were evaluated in a twelve-year community-based, prospective cohort study of urologic disease in men. Methods: During 1989-1991, 2,115 randomly selected Caucasian men, ages 40-79 years from Olmsted County, Minnesota were enrolled and followed with questionnaires biennially; 332 men were added in follow-up. A random subset (∼25%) received a urologic examination. Baseline characteristics including age, benign prostatic hyperplasia (BPH) symptoms, comorbidities, and socioeconomic factors were compared between subjects who did and did not participate after the twelfth year of follow-up. Results: Of the 2,447 men, 195 died and were excluded; 682 did not participate in 2002. Compared with men in the 40-49 year age group, men ≥ 70 years of age at baseline had a greater relative odds of dropout, 2.65 (95% CI: 1.93, 3.63). In age-adjusted analyses, relative to men without stroke, men who had suffered a stroke had a higher odds of dropout, age-adjusted OR 3.07 (95% CI: 1.49, 6.33). Presence of at least one BPH symptom was not associated with dropout, (age-adjusted OR 1.12 (95% CI: 0.93, 1.36)). Conclusion: These results provide assurance that dropout was not related to primary study outcomes. However, factors associated with dropout should be taken into account in analyses where they may be potential confounders. © 2006 Gades et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 24 条
[1]  
Szklo M., Nieto F.J., Quality assurance and control, Epidemiology: Beyond the Basics, (2004)
[2]  
Lee A.J., Garraway W.M., Simpson R.J., Fisher W., King D., The natural history of untreated lower urinary tract symptoms in middle-aged and elderly men over a period of five years, EurUrol, 34, pp. 325-332, (1998)
[3]  
Wessells H., Roy J., Bannow J., Grayhack J., Matsumoto A.M., Tenover L., Herlihy R., Fitch W., Labasky R., Auerbach S., Parra R., Rajfer J., Culbertson J., Lee M., Bach M.A., Waldstreicher J., Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia, Urology, 61, pp. 579-584, (2003)
[4]  
Roehrborn C.G., McConnell J.D., Saltzman B., Bergner D., Gray T., Narayan P., Cook T.J., Johnson-Levonas A.O., Quezada W.A., Waldstreicher J., Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes, Eur Urol, 42, pp. 1-6, (2002)
[5]  
Roehrborn C.G., Reporting of acute urinary retention in BPH treatment trials: Importance of patient follow-up after discontinuation and case definitions, Urology, 59, pp. 811-815, (2002)
[6]  
Chute C.G., Panser L.A., Girman C.J., Oesterling J.E., Guess H.A., Jacobsen S.J., Lieber M.M., The prevalence of prostatism: A population-based survey of urinary symptoms, J Urol, 150, pp. 85-89, (1993)
[7]  
Jacobsen S.J., Guess H.A., Panser L., Girman C.J., Chute C.G., Oesterling J.E., Lieber M.M., A population-based study of health care-seeking behavior for treatment of urinary symptoms: The Olmsted County Study of Urinary Symptoms and Health Status Among Men, Arch Fam Med, 2, pp. 729-735, (1993)
[8]  
Oesterling J.E., Jacobsen S.J., Chute C.G., Guess H.A., Girman C.J., Panser L.A., Lieber M.M., Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges, JAMA, 270, pp. 860-864, (1993)
[9]  
Melton III L.J., History of the Rochester Epidemiology Project, Mayo Clin Proc, 71, pp. 266-274, (1996)
[10]  
Cockett A.T., Barry M.J., Holtgrewe H.L., Sihelnick S., Williams R., McConnell J., Indications for treatment of benign prostatic hyperplasia. The American Urological Association Study, Cancer, 70, 1 SUPPL., pp. 280-283, (1992)
123